The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The company is excluding data from the affected sites to maintain the study's integrity
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Angelini Ventures has already invested €125 million in 22 startups
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Patients can now get the starting 2.5 mg dose for $299 per month
Subscribe To Our Newsletter & Stay Updated
